Brief: Mirati Therapeutics Provides Update On The Phase 3 Study Evaluating Sitravatinib In Combination With Opdivo®
24/05/2023 22:19
May 24 (Reuters) - Mirati Therapeutics Inc MRTX.O :
* MIRATI THERAPEUTICS PROVIDES UPDATE ON THE PHASE 3
SAPPHIRE
STUDY EVALUATING SITRAVATINIB IN COMBINATION WITH OPDIVO®
* MIRATI THERAPEUTICS INC - SAPPHIRE STUDY DID NOT MEET ITS
PRIMARY ENDPOINT OF OVERALL SURVIVAL AT FINAL ANALYSIS
* MIRATI THERAPEUTICS INC - PLANS TO DISCLOSE STUDY DATA AT
A
FUTURE DATE
* MIRATI THERAPEUTICS INC - PRINCIPAL INVESTIGATORS WILL BE
GIVEN
OPTION TO CONTINUE THERAPY FOR PATIENTS WHO ARE EXPERIENCING
CLINICAL BENEFIT
Source text for Eikon: ID:nPn51P8GHa
Further company coverage: MRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)